Showing results (541-550 of 789) with videos related to

Sort By:
Pageof 79
In Vivo (Athens, Greece)|February 26, 2025
Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable SurvivalLukas Goerdt, Aleksandra Stefanovic, Ralph Wirtz, et al.
British Journal of Cancer|January 1, 1997
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancerE F Solomayer, I J Diel, D Wallwiener, et al.
Breast Cancer Research and Treatment|March 23, 2006
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patientsErich F Solomayer, Sven Becker, Graziella Pergola-Becker, et al.
Breast Cancer Research and Treatment|January 18, 2018
Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancerJie Cheng, Tim Holland-Letz, Markus Wallwiener, et al.
Surgical Endoscopy|March 11, 2016
Evaluation of the HystSim™-virtual reality trainer: an essential additional tool to train hysteroscopic skills outside the operation theaterFelix Neis, Sara Brucker, Melanie Henes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II studyT Bauknecht, A Hefti, G Morack, et al.
Breast Cancer Research : BCR|September 17, 2008
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patientsTanja Fehm, Natalia Krawczyk, Erich-Franz Solomayer, et al.
International Journal of Molecular Sciences|June 19, 2024
Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast CancerLéa Louise Volmer, Dominik Dannehl, Sabine Matovina, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
Pageof 79